AstraZeneca PLC (AZN)vsBrightSpring Health Services, Inc. Common Stock (BTSG)
AZN
AstraZeneca PLC
$187.37
+1.17%
HEALTHCARE · Cap: $287.11B
BTSG
BrightSpring Health Services, Inc. Common Stock
$48.15
+1.39%
HEALTHCARE · Cap: $9.30B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 355% more annual revenue ($58.74B vs $12.91B). AZN leads profitability with a 17.4% profit margin vs 1.5%. AZN trades at a lower P/E of 27.9x. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
BTSG
Buy54
out of 100
Grade: C-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+4.1%
Fair Value
$214.51
Current Price
$187.37
$27.14 discount
Margin of Safety
+86.0%
Fair Value
$286.73
Current Price
$48.15
$238.58 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Earnings expanding 338.3% YoY
Revenue surging 29.3% year-over-year
Areas to Watch
Expensive relative to growth rate
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
ROE of 5.9% — below average capital efficiency
1.5% margin — thin
Operating margin of 3.0%
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : BTSG
The strongest argument for BTSG centers on EPS Growth, Revenue Growth. Revenue growth of 29.3% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are PEG Ratio, P/E Ratio, Revenue Growth.
Bear Case : BTSG
The primary concerns for BTSG are Return on Equity, Profit Margin, Operating Margin. A P/E of 100.3x leaves little room for execution misses. Thin 1.5% margins leave little buffer for downturns.
Key Dynamics to Monitor
AZN profiles as a value stock while BTSG is a growth play — different risk/reward profiles.
BTSG carries more volatility with a beta of 2.05 — expect wider price swings.
BTSG is growing revenue faster at 29.3% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 54/100), backed by strong 17.4% margins. BTSG offers better value entry with a 86.0% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
BrightSpring Health Services, Inc. Common Stock
HEALTHCARE · HEALTH INFORMATION SERVICES · USA
BrightSpring Health Services, Inc. (BTSG) is a prominent provider of home and community-based health services, dedicated to addressing the complex needs of a varied patient population, including those with intellectual and developmental disabilities and individuals requiring rehabilitation. The company focuses on delivering personalized care solutions facilitated by a skilled workforce, which enhances patient outcomes and quality of life. With its strategic investments in innovative technology and a firm commitment to quality, BrightSpring is well-equipped to excel in the expanding value-based care market and to effectively navigate the evolving healthcare landscape.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?